A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall Survival
time from randomisation until death due to any cause
approx. 20 months
No
GSK Clinical Trials
Study Director
GlaxoSmithKline
Australia: Human Research Ethics Committee
116513
NCT01597908
June 2012
June 2015
Name | Location |
---|---|
GSK Investigational Site | Phoenix, Arizona 85013 - 4496 |
GSK Investigational Site | Bakersfield, California 93309 |
GSK Investigational Site | Gainesville, Florida 32610 |
GSK Investigational Site | Duluth, Minnesota 55805 |
GSK Investigational Site | St. Louis, Missouri 63141 |
GSK Investigational Site | Raleigh, North Carolina 27609 |
GSK Investigational Site | Akron, Ohio 44304 |
GSK Investigational Site | Fort Worth, Texas 76104 |
GSK Investigational Site | Green Bay, Wisconsin 54301 |
GSK Investigational Site | Savannah, Georgia 31405 |
GSK Investigational Site | Royal Oak, Michigan 48073 |
GSK Investigational Site | Columbia, South Carolina 29210 |
GSK Investigational Site | Germantown, Tennessee 38138 |
GSK Investigational Site | Salem, Virginia 24153 |
GSK Investigational Site | New York, New York 10021 |
GSK Investigational Site | Birmingham, Alabama 35209 |
GSK Investigational Site | Aurora, Colorado 80012 |
GSK Investigational Site | Henderson, Nevada 89014 |
GSK Investigational Site | Edison, New Jersey 08837 |
GSK Investigational Site | Oregon City, Oregon 97045 |
GSK Investigational Site | Salt Lake City, Utah 84107 |
GSK Investigational Site | South Burlington, Vermont 05403 |